Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Yuta Suzuki, Hidehiro Kaneko, Yuicui Tamura, Akira Okada, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Katsuhito Fujiu, Koichi Node, Hideo Yasunaga, Issei Komuro
BACKGROUND: Anti-HER2 monoclonal antibody is associated with a greater risk of heart failure (HF) in female breast cancer patients. In recent years, the indication of anti-HER2 monoclonal antibodies was further expanded to stomach, colorectal, and salivary gland cancers regardless of sex in Japan. However, there have been no data on sex difference in the risk of HF after the anti-HER2 monoclonal antibody treatment. OBJECTIVES: We compared the risk of HF between male and female cancer patients treated with anti-HER2 monoclonal antibody using a nationwide population-based database...
March 20, 2023: Oncology
#2
JOURNAL ARTICLE
Sarah N Price, Jordan M Neil, Melissa Flores, Colin Ponzani, Alona Muzikansky, Lauren Ballini, Jamie S Ostroff, Elyse R Park
INTRODUCTION: Smoking after a cancer diagnosis represents a modifiable health risk. It is recommended that oncology clinicians address tobacco use among their patients using the 5As brief model: Asking about use, Advising users to quit, Assessing willingness to quit, Assisting in quit attempts (counseling and medication), and Arranging follow-up. However, cross-sectional studies have found limited adoption of 5As (especially Assist and Arrange) in oncology settings. Further investigation is needed to understand changes in, and factors associated with, 5As delivery over time...
March 9, 2023: Oncology
#3
Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.
Masaki Fujiwara, Mayako Uchida, Mirai Endo, Makoto Goto, Tadashi Shimizu
BACKGROUND: Proteasome inhibitors (PIs) are standard treatments for multiple myeloma (MM). The risk of cardiac adverse events (CAEs) with PIs has been documented with bortezomib and carfilzomib; however, only a few studies have been reported on ixazomib. Furthermore, the effects of concomitant medications including dexamethasone and lenalidomide remain unclear. OBJECTIVES: This study aimed to determine the safety signals of adverse events related to CAEs, the effect of concomitant medications, the time to the occurrence of CAEs, and the incidence of fatal clinical outcomes after the occurrence of CAEs for three PIs using the US Pharmacovigilance database...
March 8, 2023: Oncology
#4
JOURNAL ARTICLE
Brian I Carr, Vito Guerra
INTRODUCTION: Many single and combination blood tests that reflect local or systemic inflammation have been shown to be useful prognosticators in patients with a variety of tumor types. To try to clarify, this issue in patients with nonsurgically treatable hepatocellular carcinoma, multiple serum parameters were evaluated for their relationship to survival. METHODS: A prospectively collected database was interrogated of 487 patients with known hepatocellular carcinoma and documented survival and having all the inflammation parameters of interest in this study, together with baseline tumor characteristics from CT scans...
March 6, 2023: Oncology
#5
JOURNAL ARTICLE
Selin Akturk Esen, Yigit Mehmet Ozgun, Denizcan Hasturk, Gokhan Ucar, Erdal Birol Bostanci, Mehmet Sendur, Dogan Uncu
INTRODUCTION: This study examined the difference in overall survival (OS) between peritoneal metastatic gastric cancer patients who underwent neoadjuvant chemotherapy followed by cytoreductive surgery±hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) and those who did not have surgery but instead received palliative chemotherapy. METHODS: This retrospective study included 80 patients who were followed up with the diagnosis of peritoneal metastatic gastric cancer, those undergoing neoadjuvant chemotherapy followed by CRS±HIPEC (CRS±HIPEC group) and those receiving chemotherapy only (non-surgical group), in the medical oncology clinic between April 2011 and December 2021...
February 21, 2023: Oncology
#6
JOURNAL ARTICLE
Izzet Dogan, Inci Kizildag, Selnur Özkurt, Kamuran Ibis, Sezai Vatansever, Pinar Saip, Adnan Aydiner
INTRODUCTION: Patients with HER2-positive metastatic breast cancer are at risk for developing brain metastases. Different anti-HER2 treatments can be used in the management of the disease. In this study, we aimed to evaluate the prognosis and the factors affecting the prognosis in brain metastatic patients with HER2-positive breast cancer. METHODS: Clinical and pathological features of HER2-positive metastatic breast cancer patients and magnetic resonance imaging features at the onset of brain metastasis were recorded...
February 21, 2023: Oncology
#7
JOURNAL ARTICLE
Megumu Osaki, Toru Arai, Hiromitsu Sumikawa, Takayuki Takimoto, Naoko Takeuchi, Akihiro Tamiya, Kyoichi Okishio, Yoshikazu Inoue
Introduction Pleuroparenchymal fibroelastosis (PPFE) findings are associated with poor prognosis in interstitial lung disease (ILD). However, the effect of PPFE findings on the development of immune checkpoint inhibitor-related pneumonitis (ICI-pneumonitis), a life-threatening adverse event, in lung cancer patients with ILD has not been elucidated. We aimed to determine whether PPFE findings are a risk factor for ICI-pneumonitis in lung cancer patients with ILD. Methods We retrospectively examined 712 lung cancer patients, including 173 patients with background ILDs who received ICI therapy in our institute between December 2015 and May 2021...
January 23, 2023: Oncology
#8
JOURNAL ARTICLE
Yosuke Sugiyama, Taku Naiki, Yoshihiko Tasaki, Yoshihisa Mimura, Toshiki Etani, Yusuke Noda, Satoshi Nozaki, Nobuhiko Shimizu, Rika Banno, Takashi Nagai, Teruki Isobe, Ryosuke Ando, Yoshinobu Moritoki, Tomoya Kataoka, Kunihiro Odagiri, Maria Aoki, Masakazu Gonda, Takahiro Yasui, Yoko Hibi
INTRODUCTION: This study evaluated the prognostic value of a sustained high geriatric nutritional risk index (GNRI) during first-line chemotherapy for patients with metastatic urothelial carcinoma (mUC). METHODS: Between January 2018 and February 2022, 123 patients received platinum-based chemotherapy at Nagoya City University Hospital and affiliated institutions. Of these, 118 eligible patients that showed an Eastern Cooperative Oncology Group performance status (ECOG-PS) between 0 and 2 were retrospectively examined...
January 23, 2023: Oncology
#9
JOURNAL ARTICLE
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
INTRODUCTION: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab...
January 19, 2023: Oncology
#10
JOURNAL ARTICLE
Pedro Brás, Luísa Moura Branco, Ana Galrinho, Ana Teresa Timóteo, Tânia Branco Mano, Vera Ferreira, Isabel Cardoso, Alexandra Castelo, Eugénia Ferreira Pinto, Pedro Nuno Martins Coelho, Rui Rodrigues, Ana Leal, Ivan Bravio, José Fragata, Rui Cruz Ferreira
BACKGROUND: Malignant primary cardiac tumors are exceedingly rare, and despite surgical exeresis or chemotherapy, their prognosis remains poor. Cardiac invasion by metastatic tumors, while more common, also entails an unsatisfactory outcome. This study aimed to review patients diagnosed with malignant primary and secondary cardiac tumors in a tertiary center between 1995 and 2022. METHODS: Clinical data, echocardiographic, computed tomography, and magnetic resonance assessments of tumor location and morphology, histology, treatment, and survival were retrospectively analyzed...
January 19, 2023: Oncology
#11
JOURNAL ARTICLE
The impact of poorly differentiated histology on immunotherapy in advanced gastrointestinal cancers.
Amber Draper, Emily Jung, Yichun Cao, Rami P Atallah, Jeffrey M Switchenko, Sujata Kane, Jessica Guadagno, Aaron T Jones, Edith Brutcher, Olatunji B Alese
Introduction Checkpoint inhibitors (CPI) have significantly improved survival among patients with various cancer types. Prior studies have shown a correlation between immune cell infiltration and poorly differentiated cancers. This study evaluated the impact of poorly differentiated histology on survival in patients with advanced gastrointestinal cancers treated with immunotherapy. Methods This study was a retrospective, single-center analysis of patients with gastrointestinal cancers treated with checkpoint inhibitors between 2016 and 2021...
January 10, 2023: Oncology
#12
REVIEW
Alexandre Roux, Marc Zanello, Giorgia Antonia Simboli, Pascale Varlet, Arnault Tauziède-Espariat, Kévin Beccaria, Thomas Blauwblomme, Stéphanie Puget, Catherine Oppenheim, Volodia Dangouloff-Ros, Nathalie Boddaert, Frédéric Dhermain, Christelle Dufour, Jacques Grill, Fabrice Chrétien, Johan Pallud
Background Diffuse gliomas are the most frequent neoplasms in adolescent and young adults (AYAs), especially high-grade gliomas, which have the highest mortality rate. Recent histo-molecular advances are in favour of specialized therapeutic management of AYA patients, which we have analysed in this comprehensive review of the literature. Summary A literature search was conducted to identify all studies concerning diffuse gliomas and AYAs (15-39 years). We assessed epidemiology, clinical and imaging findings, histo-molecular characteristics, neurosurgical and neuro-oncological management, prognosis, and health-related quality of life...
January 5, 2023: Oncology
#13
JOURNAL ARTICLE
Osamu Shiraishi, Hiroaki Kato, Kota Momose, Yoko Hiraki, Atsushi Yasuda, Masayuki Shinkai, Motohiro Imano, Takushi Yasuda
INTRODUCTION: This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: To identify the optimal RDI, recurrence-free survival (RFS) and cumulative incidence function for recurrence (CIF) were calculated in low and high RDI groups with any cut-off points. The optimal RDI was defined as the highest RDI administered with a significant increase in either RFS or CIF...
January 4, 2023: Oncology
#14
JOURNAL ARTICLE
Takeshi Hatanaka, Atsushi Naganuma, Ai Furusawa, Yuki Tamura, Naoto Saito, Yuhei Suzuki, Takashi Hoshino, Yutaka Yata, Toshio Uraoka, Satoru Kakizaki
INTRODUCTION: We previously reported 2 cases of esophageal varices rupture during atezolizumab and bevacizumab (Atez/Bev) treatment, in which the spleen volume gradually increased. The aim of this retrospective study is to compare the chronological change in spleen volume of patients treated with Atez/Bev and lenvatinib (LEN). METHODS: Seventy-two patients (Atez/Bev group, n = 26; LEN group, n = 46) were included in this retrospective study. The splenic parenchyma area was measured based on CT imaging...
2023: Oncology
#15
Kozo Kuribayashi, Masataka Igeta, Takashi Daimon, Ibu Maede, Shinichiro Suna, Rika Okamoto, Takashi Kijima
BACKGROUND: There is no authorized treatment for malignant non-pleural mesothelioma (MNPM) worldwide. In contrast to malignant pleural mesothelioma (MPM), MNPM has not been investigated, and no treatment has been established due to its rarity. OBJECTIVES: This multicenter, open-label, single-arm, Japanese phase II trial aims at evaluating the efficacy and safety of nivolumab, an immune checkpoint inhibitor, in advanced or metastatic MNPM treatment. METHODS: This phase II trial commenced in October 2020...
December 23, 2022: Oncology
#16
JOURNAL ARTICLE
Lucia Cannella, Francesco Perri, Ottavia Clemente, Claudia Von Arx, Antonio Pizzolorusso, Maurizio Di Bonito, Alessandra Bracigliano, Massimiliano Di Marzo, Giuseppina Della Vittoria Scarpati, Annarosaria De Chiara, Salvatore Tafuto
BACKGROUND/AIM: Breast angiosarcoma is a rare and aggressive disease with a poor prognosis. Two subtypes have been identified: primary angiosarcoma (PBA) and secondary breast angiosarcoma (SBA). In this retrospective analysis, we describe and compare our institute experience with the data existing in the literature. MATERIALS AND METHODS: We included in our analysis 29 patients who received a diagnosis of PBA or SBA between 2006 and 2019. RESULTS: All patients received surgery as frontline treatment, but only 6 patients underwent to adjuvant treatment...
December 20, 2022: Oncology
#17
REVIEW
Marco Carlo Merlano, Nerina Denaro, Danilo Galizia, Andrea Abbona, Matteo Paccagnella, Silvia Minei, Ornella Garrone, Paolo Bossi
Background Among the risk factors for SCC-HN, smoking is still the most important today. Several studies agree on the effect of smoking on tumor microenvironment while the definition of former smokers and the time of smoking cessation on biologic effect differs among papers. Summary There is evidence that smoker patients have a poorer prognosis than never smokers and former smokers. Translational studies show a relationship between smoking status and gene expression and support the importance of smoking cessation, for instance, demonstrating an inverse relationship between TILs and smoking...
December 20, 2022: Oncology
#18
JOURNAL ARTICLE
Hitomi Takada, Koji Yamashita, Leona Osawa, Yasuyuki Komiyama, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Mitsuaki Sato, Shinichi Takano, Mitsuharu Fukasawa, Tatsuya Yamaguchi, Shinya Maekawa, Nobuyuki Enomoto
INTRODUCTION: Atezolizumab and bevacizumab (AB) therapy was the first-line treatment for unresectable hepatocellular carcinoma (u-HCC). However, the predictive marker of therapeutic response that can be easily used in clinical practice is still unknown. We prospectively investigated the utility of time-intensity curve (TIC) analysis using contrast-enhanced ultrasound (CEUS) as a predictive indicator of therapeutic response after the start of AB therapy. METHODS: Thirty-five patients who received AB therapy for u-HCC were included in this study...
December 14, 2022: Oncology
#19
JOURNAL ARTICLE
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Tomomitsu Matono, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa
Introduction This study investigated the relationship between nutritional status, as determined by the prognostic nutritional index (PNI), and outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). Methods The study analyzed 485 HCC patients treated with Atez/Bev. Results There were 342 patients with a low PNI (<47) and 143 with a high PNI (≥47). The median follow-up duration was 9.4 (6.0-14.3) months. Multivariate Cox hazards analysis showed that an α-fetoprotein level ≥100 ng/mL (hazard ratio (HR), 2...
December 1, 2022: Oncology
#20
JOURNAL ARTICLE
Maria Vassilakopoulou, Hsiang-Chun Chen, Xuemei Wang, Kazuto Harada, Masaaki Iwatsuki, Prajnan Das, Mariela Blum Murphy, Aurelio Matamoros, Tara Sagebiel, Catherine Devine, Irene Thomas, Elizabeth M Sanders, Namita Shanbhag, Jane E Rogers, Jeffrey H Lee, Brian Weston, Manoop S Bhutani, Wayne Hofstetter, Quynh-Nhu Nguyen, Brian D Badgwell, Jaffer A Ajani
INTRODUCTION: Gastroesophageal adenocarcinoma is relatively common in elderly patients as the incidence increases with age. However, the optimal treatment approach is not well established in this group of patients. The aim of this study is to review our experience for localized gastroesophageal adenocarcinoma in patients aged ≥ 80 years and to assess association between patient characteristics, clinical factors and overall survival in order to optimize the therapeutic approaches for this population...
November 21, 2022: Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
